Ipsen has been granted a patent for a method to suppress bone cancer-induced allodynia by administering a non-cytotoxic protease to patients. This innovative approach aims to alleviate pain in individuals suffering from bone cancer. GlobalData’s report on Ipsen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ipsen, Cancer treatment biomarkers was a key innovation area identified from patents. Ipsen's grant share as of May 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment for bone cancer-induced allodynia using non-cytotoxic protease
A recently granted patent (Publication Number: US11975055B2) discloses a method for suppressing bone cancer-induced allodynia in patients diagnosed with bone cancer. The method involves administering a non-cytotoxic protease in a therapeutically effective amount to the patient. This approach aims to alleviate the pain associated with bone cancer, particularly in cases of metastatic bone cancer, where traditional analgesics may not be as effective.
In addition to the administration of the non-cytotoxic protease, the method may also involve the use of analgesic molecules, such as opiates like morphine, to further manage the patient's pain. The patent outlines specific dosages and administration methods for both the protease and analgesic molecules, emphasizing the importance of targeting the affected areas, such as structurally damaged bones or nerve entrapment sites. By combining these treatments, the method offers a comprehensive approach to addressing bone cancer-induced allodynia, potentially improving the quality of life for patients with bone cancer, even in cases where they may have additional cancers beyond bone cancer.
To know more about GlobalData’s detailed insights on Ipsen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
